What is uterine carcinosarcoma?
Uterine carcinosarcoma (UCS) is a rare, high-grade cancer of the womb (uterus). It contains two kinds of cancer cell mixed together: a carcinoma part, which looks like cancer of the womb lining, and a sarcoma part, which looks like cancer of connective tissue such as muscle, cartilage or bone.
It used to be called malignant mixed Mullerian tumour (MMMT). It was once grouped with the uterine sarcomas, but research has shown that the sarcoma part grows out of the carcinoma part. For this reason doctors now treat carcinosarcoma as a very aggressive type of endometrial cancer rather than a true sarcoma (Matsuzaki et al., 2021).
UCS makes up about 5% of womb cancers, and the number of cases has been slowly rising. It mostly affects women after the menopause, usually in their 60s and 70s. The most common first sign is bleeding from the vagina after the menopause.
Because it often spreads early, UCS is responsible for a much larger share of deaths from womb cancer than its small numbers would suggest (Toboni et al., 2025). Treatment usually combines surgery and chemotherapy, sometimes with radiotherapy.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | High-grade endometrial cancer with carcinoma and sarcoma components |
| Older name | Malignant mixed Mullerian tumour (MMMT) |
| How common | About 5 in 100 womb cancers |
| Typical age | Mostly over 60; median about 65-70 |
| Main symptom | Bleeding after the menopause |
| Spread at diagnosis | Often beyond the uterus, to lymph nodes, abdomen or lungs |
| Main treatment | Hysterectomy and removal of ovaries and tubes, then chemotherapy |
| Standard chemotherapy | Carboplatin and paclitaxel |
| Outlook | Serious; about one-third alive at 5 years overall |
2. Types of uterine carcinosarcoma
The two components
| Component | What it looks like | Notes |
|---|---|---|
| Carcinoma | Usually serous or endometrioid-type high-grade cancer; sometimes clear cell | Drives spread to lymph nodes and the abdomen |
| Sarcoma | Spindle cells and other mesenchymal cells | Can dominate the tumour |
Homologous and heterologous sarcoma
| Type | Meaning |
|---|---|
| Homologous | The sarcoma looks like tissue normally found in the uterus, such as smooth muscle or stromal cells |
| Heterologous | The sarcoma contains tissue not normally found in the uterus, such as cartilage, bone or skeletal muscle |
Some studies suggest that a heterologous sarcoma or a sarcoma component making up more than half of the tumour is linked with a poorer outcome (Matsuzaki et al., 2021).
Related tumours elsewhere
Carcinosarcoma can also arise in the ovary, fallopian tube, cervix or vagina. These are much rarer and are treated in similar ways.
How it differs from other womb cancers
| Feature | Common (endometrioid) womb cancer | Carcinosarcoma |
|---|---|---|
| Grade | Often low grade | Always high grade |
| Spread at diagnosis | Usually confined to the uterus | Frequently beyond the uterus |
| Link with oestrogen | Strong | Weaker |
| Usual treatment | Surgery alone for many | Surgery plus chemotherapy for most |
| Outlook | Generally good | Considerably poorer |
3. Causes and risk factors
The exact cause is not known. Many risk factors are shared with other womb cancers.
| Risk factor | Notes |
|---|---|
| Older age | Most cases are after the menopause |
| Black ethnicity | Black women are affected more often and tend to have poorer outcomes |
| Obesity | Raises oestrogen levels after the menopause |
| Tamoxifen use | Long-term use for breast cancer slightly increases the risk |
| Previous pelvic radiotherapy | Linked with carcinosarcoma years later |
| Never having been pregnant | Associated with womb cancers in general |
| Lynch syndrome | An inherited condition that raises the risk of womb and bowel cancers; occasionally involved |
Gene changes
| Gene change | Notes |
|---|---|
| TP53 | Mutated in most tumours; similar to serous endometrial cancer |
| PIK3CA, PTEN, FBXW7, ARID1A | Common additional changes |
| HER2 (ERBB2) | Over-active in a proportion; a possible treatment target |
| Mismatch repair deficiency | Present in a small minority; may respond to immunotherapy |
Most of these changes occur only in the tumour. Testing for Lynch syndrome is offered if the tumour shows mismatch repair deficiency.
4. How does it look
Inside the womb
| Feature | Description |
|---|---|
| Shape | A bulky, soft, polyp-like mass filling the womb cavity |
| Size | Often large; may stretch the uterus |
| Position | Can push down through the cervix and be visible at the vaginal opening |
| Surface | Fleshy, with bleeding and areas of dead tissue |
| Cut surface | Mixed appearance; sometimes gritty bone or glassy cartilage |
On scans
Transvaginal ultrasound usually shows a thickened womb lining or a mass in the cavity. MRI of the pelvis shows how deeply the tumour has grown into the muscle wall and cervix. CT of the chest, abdomen and pelvis, or PET-CT, looks for spread to lymph nodes, the omentum (fatty apron in the abdomen), liver and lungs.
Under the microscope
| Feature | Description |
|---|---|
| Two cell types | Malignant glands next to malignant spindle or other mesenchymal cells |
| Grade | Both parts are high grade |
| Necrosis | Often extensive |
| Lymphovascular invasion | Common |
| Stains | p53 (abnormal in most), mismatch repair proteins and HER2 |
5. Symptoms
Common symptoms
- Bleeding from the vagina after the menopause
- Heavy, irregular or prolonged bleeding in women nearing the menopause
- Watery or bloodstained discharge, sometimes smelly
- Pain or pressure in the pelvis
- A lump felt or seen at the vaginal opening
Less common symptoms
| Symptom | What it may mean |
|---|---|
| Swollen abdomen | Fluid or tumour deposits in the abdomen |
| Leg swelling | Pressure on lymph nodes or veins |
| Cough or breathlessness | Spread to the lungs |
| Tiredness and pale skin | Anaemia from bleeding |
| Weight loss | Advanced disease |
When to seek medical advice
Any bleeding after the menopause should be checked by a doctor, even if it is a small amount or happens only once. Most causes are not cancer, but early assessment allows prompt diagnosis when it is.
6. Diagnosis
| Test | Purpose |
|---|---|
| Pelvic examination | Checks the vagina, cervix and any visible mass |
| Transvaginal ultrasound | Measures the womb lining |
| Endometrial biopsy | A thin tube takes a sample from the womb lining |
| Hysteroscopy | A camera looks inside the womb and samples abnormal areas |
| MRI pelvis | Shows local extent |
| CT or PET-CT | Checks for spread |
| Blood tests | Blood count, kidney and liver function; CA-125 may be raised |
| Final pathology after surgery | Confirms the diagnosis and stage |
A biopsy may show only the carcinoma part, so the full diagnosis is sometimes made only after hysterectomy.
Staging
UCS is staged with the FIGO system used for endometrial cancer.
| Stage | What it means |
|---|---|
| Stage I | Cancer confined to the body of the uterus |
| Stage II | Spread into the cervix |
| Stage III | Spread to the ovaries, tubes, vagina, pelvic tissues or lymph nodes |
| Stage IV | Spread to the bladder, bowel, inside of the abdomen or distant organs |
7. Treatment
Treatment is planned by a gynaecological oncology team.
Surgery
| Procedure | Notes |
|---|---|
| Total hysterectomy | Removes the uterus and cervix |
| Bilateral salpingo-oophorectomy | Removes both ovaries and fallopian tubes |
| Lymph node assessment | Sentinel node biopsy or removal of pelvic and para-aortic nodes |
| Omentectomy and peritoneal biopsies | Checks the abdomen for hidden spread |
| Debulking surgery | Removes as much visible tumour as possible in advanced disease |
Surgery may be done by keyhole (laparoscopic or robotic) or open methods, depending on the size of the uterus and the extent of disease.
Chemotherapy
Chemotherapy is recommended for most women, even with early-stage disease, because the risk of spread is high.
| Regimen | Notes |
|---|---|
| Carboplatin and paclitaxel | Standard first choice; a large randomised trial showed it was at least as effective as paclitaxel with ifosfamide (Powell et al., 2022) |
| Paclitaxel and ifosfamide | An older alternative with more confusion and bladder bleeding |
| Number of cycles | Usually 6, given every 3 weeks |
In that trial of 449 women with UCS, median survival was 37 months with carboplatin and paclitaxel compared with 29 months with paclitaxel and ifosfamide, and the cancer was controlled for longer (Powell et al., 2022).
Radiotherapy
| Type | When it may be used |
|---|---|
| Vaginal brachytherapy | Internal radiotherapy to the top of the vagina to lower the risk of local recurrence |
| External beam pelvic radiotherapy | For disease in the pelvis or lymph nodes, sometimes combined with chemotherapy |
| Palliative radiotherapy | Controls bleeding or pain |
Treatment of advanced or recurrent disease
| Option | Notes |
|---|---|
| Further chemotherapy | Responses are less frequent after the first line |
| Immunotherapy | Checkpoint inhibitors, alone or with chemotherapy, especially for mismatch repair-deficient tumours |
| Lenvatinib with pembrolizumab | An option for some recurrent endometrial cancers |
| HER2-directed drugs | For tumours with high HER2 |
| Clinical trials | Testing new targeted and immune treatments |
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Pain, wound problems, blood clots, early menopause symptoms if not already menopausal |
| Lymph node removal | Leg swelling (lymphoedema) |
| Chemotherapy | Tiredness, hair loss, low blood counts, infection risk, numbness in hands and feet |
| Radiotherapy | Diarrhoea, bladder irritation, vaginal dryness and narrowing |
What treatment involves day to day
| Stage | What to expect |
|---|---|
| Keyhole surgery | Often 1-2 nights in hospital; back to light activity in 2-3 weeks |
| Open surgery | Around 3-5 nights in hospital; recovery over 6 weeks |
| Chemotherapy | A day-unit visit every 3 weeks for about 4-5 months |
| Brachytherapy | A few short outpatient sessions |
8. Outlook (prognosis)
UCS has a poorer outlook than most other womb cancers. Across all stages, about one-third of women are alive at 5 years, and this figure has changed little over several decades (Matsuzaki et al., 2021).
| Factor | Effect on outlook |
|---|---|
| Stage I disease | Much better than average; many women are cured |
| Spread to lymph nodes or abdomen | Higher risk of recurrence |
| Complete removal of visible tumour | Better outcome |
| Sarcoma-dominant tumour | Linked with poorer survival in some studies |
| Chemotherapy after surgery | Lowers the risk of recurrence |
When the cancer comes back, it often does so within 2 years, in the abdomen, pelvis or lungs.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic visits every 3-4 months for 2-3 years | Examination and review of symptoms |
| Every 6 months up to 5 years | Continued monitoring |
| CT scans | Often every 6 months in the first years, depending on stage |
| Vaginal examination | Checks the top of the vagina |
| Support for late effects | Lymphoedema, menopause symptoms, sexual health |
10. Living with uterine carcinosarcoma
- Report new bleeding, pain, swelling or cough promptly
- Use vaginal dilators if advised after brachytherapy
- Ask about lymphoedema care if your legs swell
- Stay active within your limits to help with tiredness and strength
- Discuss genetic testing if your tumour is mismatch repair-deficient
- Seek emotional support from your team, specialist nurses or gynaecological cancer charities
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is carcinosarcoma a sarcoma? | Not really; it behaves as a high-grade endometrial cancer |
| Is it the same as MMMT? | Yes, MMMT is the older name |
| Do I need chemotherapy if it is stage I? | It is usually recommended because of the high risk of spread |
| Is it hereditary? | Usually not, but a few cases are linked with Lynch syndrome |
| Can tamoxifen cause it? | Long-term tamoxifen slightly raises the risk; its benefits for breast cancer usually outweigh this |
| Will I go into menopause? | Yes, if you have not already, because the ovaries are removed |
| Does immunotherapy work? | It helps some women, especially those with mismatch repair-deficient tumours |
| Can I keep my ovaries? | Usually not, because the cancer can spread to them and most women are past the menopause |
12. Questions to ask your care team
- What stage is my cancer, and were the lymph nodes involved?
- Was all visible tumour removed?
- Which chemotherapy do you recommend, and for how many cycles?
- Will I need radiotherapy?
- Has my tumour been tested for mismatch repair, p53 and HER2?
- Am I eligible for any clinical trials?
Resources
- Matsuzaki, S. et al. (2021) ‘Uterine carcinosarcoma: contemporary clinical summary, molecular updates, and future research opportunity’, Gynecologic Oncology, 160(2), pp. 586-601.
- Pezzicoli, G. et al. (2021) ‘Uterine carcinosarcoma: an overview’, Critical Reviews in Oncology/Hematology, 163, 103369.
- Powell, M.A. et al. (2022) ‘Randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and ifosfamide in patients with carcinosarcoma of the uterus or ovary: an NRG Oncology trial’, Journal of Clinical Oncology, 40(9), pp. 968-977.
- Toboni, M. et al. (2025) ‘Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma’, International Journal of Gynecological Cancer, 35(3), 101672.
- National Cancer Institute (2026) Endometrial Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/uterine/hp/endometrial-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.